2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region

The unique characteristics of patients with acute coronary syndrome in the Asia-Pacific region mean that international guidelines on the use of dual antiplatelet therapy (DAPT) cannot be routinely applied to these populations. Newer generation P2Y12 inhibitors (i.e. ticagrelor and prasugrel) have de...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jack WC Tan, Derek P Chew, Muhamad Ali SK Abdul Kader, Junya Ako, Vinay K Bahl, Mark Chan, Kyung Woo Park, Praveen Chandra, I-Chang Hsieh, Do Quang Huan, Sofian Johar, Dafsah Arifa Juzar, Byeong-Keuk Kim, Cheol Whan Lee, Michael Kang-Yin Lee, Yi-Heng Li, Wael Almahmeed, Eric Oliver Sison, Doreen Tan, Yu-Chen Wang, Shiuan Jong Yeh, Gilles Montalescot
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2021
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/eabee3b36e394956b947e256170f156e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eabee3b36e394956b947e256170f156e
record_format	dspace
spelling	oai:doaj.org-article:eabee3b36e394956b947e256170f156e2021-12-04T16:03:56Z2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region10.15420/ecr.2020.401758-37641758-3756https://doaj.org/article/eabee3b36e394956b947e256170f156e2021-03-01T00:00:00Zhttps://www.ecrjournal.com/articleindex/ecr.2020.40https://doaj.org/toc/1758-3756https://doaj.org/toc/1758-3764The unique characteristics of patients with acute coronary syndrome in the Asia-Pacific region mean that international guidelines on the use of dual antiplatelet therapy (DAPT) cannot be routinely applied to these populations. Newer generation P2Y12 inhibitors (i.e. ticagrelor and prasugrel) have demonstrated improved clinical outcomes compared with clopidogrel. However, low numbers of Asian patients participated in pivotal studies and few regional studies comparing DAPTs have been conducted. This article aims to summarise current evidence on the use of newer generation P2Y12 inhibitors in Asian patients with acute coronary syndrome and provide recommendations to assist clinicians, especially cardiologists, in selecting a DAPT regimen. Guidance is provided on the management of ischaemic and bleeding risks, including duration of therapy, switching strategies and the management of patients with ST-elevation and non-ST-elevation MI or those requiring surgery. In particular, the need for an individualised DAPT regimen and considerations relating to switching, de-escalating, stopping or continuing DAPT beyond 12 months are discussed.Jack WC TanDerek P ChewMuhamad Ali SK Abdul KaderJunya AkoVinay K BahlMark ChanKyung Woo ParkPraveen ChandraI-Chang HsiehDo Quang HuanSofian JoharDafsah Arifa JuzarByeong-Keuk KimCheol Whan LeeMichael Kang-Yin LeeYi-Heng LiWael AlmahmeedEric Oliver SisonDoreen TanYu-Chen WangShiuan Jong YehGilles MontalescotRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENEuropean Cardiology Review , Vol 16, Iss , Pp - (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Jack WC Tan Derek P Chew Muhamad Ali SK Abdul Kader Junya Ako Vinay K Bahl Mark Chan Kyung Woo Park Praveen Chandra I-Chang Hsieh Do Quang Huan Sofian Johar Dafsah Arifa Juzar Byeong-Keuk Kim Cheol Whan Lee Michael Kang-Yin Lee Yi-Heng Li Wael Almahmeed Eric Oliver Sison Doreen Tan Yu-Chen Wang Shiuan Jong Yeh Gilles Montalescot 2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region
description	The unique characteristics of patients with acute coronary syndrome in the Asia-Pacific region mean that international guidelines on the use of dual antiplatelet therapy (DAPT) cannot be routinely applied to these populations. Newer generation P2Y12 inhibitors (i.e. ticagrelor and prasugrel) have demonstrated improved clinical outcomes compared with clopidogrel. However, low numbers of Asian patients participated in pivotal studies and few regional studies comparing DAPTs have been conducted. This article aims to summarise current evidence on the use of newer generation P2Y12 inhibitors in Asian patients with acute coronary syndrome and provide recommendations to assist clinicians, especially cardiologists, in selecting a DAPT regimen. Guidance is provided on the management of ischaemic and bleeding risks, including duration of therapy, switching strategies and the management of patients with ST-elevation and non-ST-elevation MI or those requiring surgery. In particular, the need for an individualised DAPT regimen and considerations relating to switching, de-escalating, stopping or continuing DAPT beyond 12 months are discussed.
format	article
author	Jack WC Tan Derek P Chew Muhamad Ali SK Abdul Kader Junya Ako Vinay K Bahl Mark Chan Kyung Woo Park Praveen Chandra I-Chang Hsieh Do Quang Huan Sofian Johar Dafsah Arifa Juzar Byeong-Keuk Kim Cheol Whan Lee Michael Kang-Yin Lee Yi-Heng Li Wael Almahmeed Eric Oliver Sison Doreen Tan Yu-Chen Wang Shiuan Jong Yeh Gilles Montalescot
author_facet	Jack WC Tan Derek P Chew Muhamad Ali SK Abdul Kader Junya Ako Vinay K Bahl Mark Chan Kyung Woo Park Praveen Chandra I-Chang Hsieh Do Quang Huan Sofian Johar Dafsah Arifa Juzar Byeong-Keuk Kim Cheol Whan Lee Michael Kang-Yin Lee Yi-Heng Li Wael Almahmeed Eric Oliver Sison Doreen Tan Yu-Chen Wang Shiuan Jong Yeh Gilles Montalescot
author_sort	Jack WC Tan
title	2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region
title_short	2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region
title_full	2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region
title_fullStr	2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region
title_full_unstemmed	2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region
title_sort	2020 asian pacific society of cardiology consensus recommendations on the use of p2y12 receptor antagonists in the asia-pacific region
publisher	Radcliffe Medical Media
publishDate	2021
url	https://doaj.org/article/eabee3b36e394956b947e256170f156e
work_keys_str_mv	AT jackwctan 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion AT derekpchew 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion AT muhamadaliskabdulkader 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion AT junyaako 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion AT vinaykbahl 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion AT markchan 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion AT kyungwoopark 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion AT praveenchandra 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion AT ichanghsieh 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion AT doquanghuan 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion AT sofianjohar 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion AT dafsaharifajuzar 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion AT byeongkeukkim 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion AT cheolwhanlee 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion AT michaelkangyinlee 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion AT yihengli 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion AT waelalmahmeed 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion AT ericoliversison 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion AT doreentan 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion AT yuchenwang 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion AT shiuanjongyeh 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion AT gillesmontalescot 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion
_version_	1718372707961143296

2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region

Ejemplares similares